Skip to main content

Table 4 Preoperative status

From: Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy

 

Neoadjuvant ( n= 80)

Adjuvant ( n= 90)

P

White blood cells

4.73

5.63

<0.001

Platelets

156.7

240.4

<0.001

Hemoglobin

125.1

121.5

0.291

Serum albumin

39.4

38.9

0.520

CEA >5 μg/L

17 (21.8%)

14 (16.3%)

0.427

CA 19–9 > 37 μg/mL

13 (16.7%)

16 (18.6%)

0.839

Comorbidity

43 (53.8%)

54 (60.0%)

0.441

Cardiovascular

31 (38.8%)

28 (31.1%)

0.335

Pulmonary

3 (3.8%)

5 (5.6%)

0.724

Diabetes mellitus

2 (2.5%)

9 (10.0%)

0.062

Gastrointestinal disease

7 (8.8%)

4 (4.4%)

0.352

Urinary

4 (5.0%)

1 (1.1%)

0.189

Liver

4 (5.0%)

8 (8.9%)

0.381

History of surgery

22 (27.5%)

21 (23.3%)

0.597

Other

12 (15.0%)

20 (22.2%)

0.245

  1. CA 19–9 cancer antigen 19–9, CEA carcinoembryonic antigen.